Trials / Completed
CompletedNCT03242590
Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).
Validation of Dosing Regimen of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 95 (actual)
- Sponsor
- Lipocine Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter, open-label, one treatment study evaluating the efficacy of LPCN 1021 in adult hypogonadal male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LPCN 1021 | Oral testosterone undecanoate |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2017-03-01
- Completion
- 2017-07-01
- First posted
- 2017-08-08
- Last updated
- 2019-10-23
- Results posted
- 2019-09-11
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03242590. Inclusion in this directory is not an endorsement.